Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% w/ Dextrose 5% provides essential and non-essential amino acids for protein synthesis and dextrose for caloric support, aiding in nitrogen balance and maintenance of lean body mass in parenteral nutrition.
Aminosyn II 3.5% in Dextrose 25% is a combination of amino acids and dextrose for parenteral nutrition. Amino acids provide nitrogen and essential substrates for protein synthesis, while dextrose provides a caloric source to prevent protein catabolism. The mechanism involves infusion into the bloodstream, bypassing gastrointestinal digestion, to maintain or restore nitrogen balance and provide energy.
Intravenous infusion. Adult dose: 500-1000 mL per day, infused at a rate not exceeding 100 mL/hour, adjusted based on metabolic requirements and tolerance.
Intravenous infusion. Amino acid dose based on protein requirements: 0.8-1.0 g/kg/day for stable patients, up to 1.5-2.0 g/kg/day for catabolic states. Dextrose dose based on caloric needs: typically 150-300 g/day. Infuse via central line at rates not exceeding 0.5 g/kg/hour dextrose. Typical starting rate: 50-100 mL/hr, titrated based on metabolic tolerance.
None Documented
None Documented
Not applicable as a single entity; amino acids and dextrose are endogenous substances. Metabolic half-life of infused amino acids ~10-30 min; dextrose ~15-20 min. Continuous infusion results in steady state.
Amino acids have variable half-lives (minutes to hours); dextrose has a plasma half-life of ~2 hours under euglycemic conditions. Clinically, continuous infusion maintains steady state.
Renal excretion of amino acids and dextrose metabolites (CO2, water). Urea nitrogen accounts for ~80-90% of nitrogen excretion. Unchanged dextrose minimal (<1%). Biliary/fecal excretion negligible.
Renal excretion of amino acids as urea and ammonia; dextrose is metabolized to CO2 and water. Approximately 90% of infused amino nitrogen is recovered in urine as urea within 24 hours. Dextrose is completely metabolized.
Category C
Category C
Amino Acid Solution
Amino Acid Solution